Compare MNDR & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNDR | GRI |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.6M |
| IPO Year | 2023 | 2020 |
| Metric | MNDR | GRI |
|---|---|---|
| Price | $2.18 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | ★ 107.4K | 39.2K |
| Earning Date | 03-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $608,852.40 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.40 | $0.18 |
| 52 Week High | $5.42 | $6.70 |
| Indicator | MNDR | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 30.89 |
| Support Level | $0.72 | $0.20 |
| Resistance Level | $3.90 | $2.24 |
| Average True Range (ATR) | 0.26 | 0.10 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 0.00 | 4.44 |
Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services, and the Sale of medicine and medical devices. The majority of the company's revenue is derived from the Telemedicine and other services segment. Geographically, it derives revenue from Singapore.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.